Search clinical trials for: Trastuzumab Injection

Total 10886 results

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini

China
Genor Biopharma Co., Ltd.

Completed

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Metastatic Breast Cancer

Australia
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
University Medical Center Groningen

Completed

Clinical Value of 89Zr-trastuzumab PET

Metastatic Breast Cancer

Netherlands
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
Pfizer

Completed

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

Healthy

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
University Medical Center Groningen
Amsterdam UMC, location VUmc; University Medical Center Nijmegen

Active, not recruiting

IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer (IMPACT-MBC)

Metastatic Breast Cancer

Netherlands
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer

China
Afyonkarahisar Health Sciences University

Completed

The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome (PRP)

Musculoskeletal Diseases | Shoulder Pain | Rotator Cuff Tendinopathy | Rotator Cuff Syndrome

Turkey
Jonsson Comprehensive Cancer Center

Completed

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Breast Cancer

United States
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
Hoffmann-La Roche

Completed

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer (PrefHER)

Breast Neoplasms

France, Spain, Sweden, Denmark, Russian Federation, Canada, Germany, United Kingdom, Italy, Turkey, Poland, Switzerland
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Jules Bordet Institute

Withdrawn

Kadcyla In pAtients With bRAin Metastasis (KIARA)

Metastatic HER2-positive Breast Cancer With Brain Metastasis
MedSIR
Hoffmann-La Roche

Not yet recruiting

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER)

HER2-positive Breast Cancer
Consorzio Oncotech
Roche Pharma AG

Recruiting

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Breast Cancer

Italy
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Post-Operative Pain

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HER2-positive Breast Cancer

China
Bio-Thera Solutions

Active, not recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Advanced Solid Tumor

China
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Post-Operative Pain

Korea, Republic of
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention (IA)

HIV Infections

United States
Tanvex BioPharma USA, Inc.

Completed

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast Cancer

Belarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
GlaxoSmithKline

Completed

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
UNICANCER
Seagen Inc.

Recruiting

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease (ETIC-LM)

HER2-positive Metastatic Breast Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis

France
Rehabilitace MUDr. Hasan Mezian s.r.o.

Unknown

Effectiveness of Ultrasound Guided Corticoanesthetic Injection in Carpal Tunnel Syndrome

Carpal Tunnel Syndrome

Czechia
Fudan University
Hoffmann-La Roche

Unknown

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer (PCH)

Breast Cancer

China
University of Leipzig
Celgene Corporation

Recruiting

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions (LENNON)

Myelodysplastic Syndromes | Anemia

Germany
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

Post-Operative Pain

Korea, Republic of
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
RemeGen Co., Ltd.

Completed

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditions

United States, Puerto Rico
Samsung Bioepis Co., Ltd.

Terminated

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Breast Neoplasms

Ukraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
Fudan University

Completed

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Breast Cancer

China
Orano Med LLC

Completed

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Stomach Neoplasms | Breast Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Peritoneal Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Gynecological Malignancy

China
Indiana University

Completed

Prospective Study of Celiac Block Injection: 1 vs. 2

Pancreatic Cancer | Chronic Pancreatitis

United States
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Fujian Medical University Union Hospital

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Breast Cancer | Adjuvant Therapy

China

Search clinical trials for: Trastuzumab Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations